Request for Free Sample

Syndromic Multiplex Diagnostics Market Report Scope & Overview:

Syndromic multiplex diagnostics market size was valued at USD 2.87 billion in 2024 and is expected to reach USD 4.13 billion by 2032, growing at a CAGR of 4.71% over the forecast period of 2025-2032.

The global syndromic multiplex diagnostics market is growing significantly, driven by the increasing requirement for fast, precise, and multispecialty diagnostic solutions for infectious diseases. Growing incidences of respiratory, gastrointestinal, and sexually transmitted infections are expected to increase the adoption rate. Continuous technological progress in the field of molecular diagnostics and rising awareness regarding the early detection of diseases are also anticipated to boost the growth of this market. The post-pandemic healthcare infrastructure enhancement, COVID-19 positive diagnosis testing, also supports growing market share within clinical labs, hospitals, and point-of-care settings globally.

The U.S. syndromic multiplex diagnostics market size was valued at USD 0.89 billion in 2024 and is expected to reach USD 1.25 billion by 2032, growing at a CAGR of 4.50% over the forecast period of 2025-2032.

The North American syndromic multiplex diagnostics market is led by the U.S., owing to a highly developed health care system coupled with a high adoption rate for molecular diagnostics and a high disease burden of infectious diseases. Now, the availability of key players in the industry and continuous R&D investments boost the growth. Moreover, therapy adoption, reimbursement policies, and test adoption in clinical settings play an important role in driving market growth.

Market Dynamics:

Drivers

  • Rise of Infectious Diseases and Respiratory Infections are the Major Factors Driving the Market Expansion

The escalating incidence of infectious diseases such as influenza, respiratory syncytial virus (RSV), and novel pathogens such as COVID-19 has led to a pressing need for fast and reliable diagnostics. The testing of multiple pathogens in syndromic multiplex panels can assist with co-infections and expedite effective therapy in those critically ill patients where every minute counts. Rapid identification of the actual cause of infection also supports their widespread adoption by healthcare providers.

In Egypt during the COVID-19 pandemic, 75.9% of SARI patients who tested positive for COVID-19 during the pandemic had evidence of respiratory co-infections with other pathogens, revealing the considerable burden of co-existing infections.

In the U.S., there has been widespread acceptance of multiplex PCR respiratory panels at the expense of single-pathogen tests. Hospital epidemiologists used these panels to demonstrate improved diagnosis and patient outcomes, with greater sensitivity and rapid turnaround times over culture-based gold standards.

  • The Syndromic Multiplex Diagnostics Market is Driven by the Growing Demand for Rapid Diagnostic Solutions

In emergency and critical care settings, rapid and accurate diagnosis is crucial to the onset of appropriate therapy and limitation of the duration of hospitalization. With an average turnaround time of an hour, syndromic multiplex diagnostics provide the clinician with actionable test results much faster than traditional diagnostic tests. This speed facilitates clinical decision-making, enhances patient outcomes, and supports efficient infection control, which makes these solutions more and more favorable in both high-income and resource-limited environments.

Researchers led by NYU Abu Dhabi have created a paper-based diagnostic device—named the RCP‑Chip—that can identify COVID-19 and other infectious diseases in less than 10 minutes without requiring complex laboratory equipment to use.

In April 2023, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) in the U.S. announced a request to support the expansion of over-the-counter (OTC) multiplex rapid tests, such as COVID-19-influenza differentiation kits, based on the acute demand for rapid and preliminary diagnostics capable of being used in the field.                              

Restraint

  • Expensive Syndromic Multiplex Panels and Instrumentation are Restraining the Market from Growing

Syndromic multiplex diagnostic platforms are commercially available, rapid, and can test for many pathogens with one assay. But they are expensive, financially, that is. It has high-capital equipment (multiplex PCR systems, molecular diagnostic analyzers) and requires a significant upfront investment (thousands of dollars) per site per test. Per-test costs of these single testing panels or cartridges are considerably higher than conventional diagnostic approaches, and these approaches are usually proprietary and consumables-based. This impedes adoption in resource-restricted environments, such as under-resourced clinics, developing countries, and indeed anywhere with a restricted healthcare budget.

The continuous need for maintenance, software updates, and instrument calibration contributes to the overall cost of ownership and makes it difficult for facilities to use this as a long-term investment, particularly when testing volumes may be low. Consequently, due to the clear clinical value offered by these multiplex diagnostics, these aforementioned cost-related limiting characteristics strongly restrict widespread implementation of syndromic multiplex diagnostics in countless healthcare systems.

Segmentation Analysis:

By Product & Service

Due to the repeated usage of assay kits, cartridges, and the requirement of various consumables in high-throughput diagnostic workflows, the Reagents & Consumables segment held the dominating share of the syndromic multiplex diagnostics market in 2024, with 48.26%. Such products are an integral part of routine testing and are especially necessary in the diagnostics of infectious diseases, where testing is conducted repeatedly in hospitals and clinical lab settings. Segment revenue was also boosted by their comparatively lower cost per test and increasing acceptance of syndromic panels for respiratory, GI, and bloodstream infections.

The software & services segment is projected to be the fastest-growing segment during the forecast period, as there is an increasing adoption of cloud-based diagnostic platforms integrated with AI-powered analytics. With the laboratories and health-care providers paying significant attention to data-based decision making, the need for complex software providing real-time data analytics, the interpretation of tests, and interconnectivity of the systems is expected to rise rapidly. In addition, continued updates and contracts for value-added services help create these sustainable revenue models that will underpin strong growth for this segment.

By Syndrome/Disease Type

The respiratory infections segment dominated the syndromic multiplex diagnostics market share in 2024 with 34.12%, maintaining its lucrative position during the forecast period, owing to the high global burden of respiratory diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and pneumonia. These infections are most common but not exclusive to the pediatric, elderly, and immunocompromised, causing the need for rapid, comprehensive diagnostic panels. In addition, since respiratory infections frequently share a common clinical presentation, the ability for multiplex diagnostics to provide differential diagnosis and prompt treatment decisions would be particularly useful.

During the forecast period, the gastrointestinal infections segment is expected to grow at the fastest pace due to the increasing incidence of foodborne diseases globally, traveler's diarrhea, and hospital-acquired infections in both developed and developing regions. Enteric pathogens are of growing interest due to enhanced access to molecular diagnostics and expanding implementation of syndromic testing in emergency departments and outpatient settings.

By Technology

Due to its common practice in clinical settings and associated high sensitivity and short turnaround time for cost-effectiveness, the PCR-based segment of the syndromic multiplex diagnostics market accounted for the largest share by technology in 2024. For many infectious diseases, PCR technology has remained the gold standard for diagnosis for decades, and its multiplexing ability has made it possible to simultaneously detect multiple pathogens from a single patient sample. However, PCR panels are well established, FDA-cleared, integrated into existing lab workflow, and validated in large cohorts for syndromic diagnosis and hence remain a gold standard for timely and accurate syndromic diagnosis in respiratory, gastrointestinal, and CNS infection.

During the forecast period, the NGS segment is anticipated to be the fastest-growing as it offers the deepest view of pathogen detection capability, including detection of rare, novel, or co-infecting agents, compared to the other methods. The increasing prevalence of precision diagnostics and the national outbreak surveillance are anticipated to propel the number of NGS-based syndromic panels being developed, and the increasing use of metagenomic solutions in microbiology is also expected to propel the metagenomics clinical market. Increase in demand for clinical microbiology diagnostic solutions owing to the increasing prevalence of infectious diseases.

By End User

Due to the high throughput capabilities, specialized equipment, and skilled personnel available to support complex and large-scale testing workflows, the diagnostic laboratories segment was the leading end user in the syndromic multiplex diagnostics market in 2024.  Therefore, often chosen for multiplex molecular diagnostics due to their ability to handle a large number of samples, and quality assurance and regulatory control. Moreover, as centralized diagnostic labs continue to be integrated with public health surveillance systems and research projects, there has been a growing interest in syndromic multiplex panels for the simultaneous detection of multiple pathogens.

The hospitals & clinics segment is anticipated to be the fastest growing during the forecast years, due to the high adoption rate of point-of-care testing, and the growing need for rapid diagnostics in these acute care settings. As the high demand for rapid decision making among clinicians continues to increase, hospitals and clinics are increasingly investing in syndromic multiplex platforms that allow clinicians to obtain answers sooner to help better manage treatment for patients suffering from a respiratory infection, gastrointestinal disease, or sepsis.

Regional Analysis:

The syndromic multiplex diagnostics market, dominated by North America, with a 40.6% in 2024 characterized by developed healthcare structures, quick adoption of advanced diagnostic technologies, and the dominance of key market players. High healthcare expenditure with extensive laboratory networks and regulatory support for molecular diagnostic solutions in the more developed West region of the country lends further support to the market. In addition, better clinician awareness of syndromic testing and strong reimbursement mechanisms continue to support rapid deployment in hospitals, diagnostic centers, and point-of-care locations.

The Asia Pacific region is expected to witness the highest growth during the forecast period, with 5.77% CAGR on account of booming healthcare expenditure, increasing diagnostic capacities, and rising incidents of infectious diseases. High patient population, high infection rates in countries such as China, India, and Japan, resulting in an increase in the demand for rapid and accurate diagnostic tools. The market is also being driven by government initiatives to update healthcare infrastructure and by the growth of the private healthcare market. Syndromic multiplex testing offers an economical and scalable solution that is ideally suited to resource-poor and developing economies across the region.

Syndromic multiplex diagnostics market trend in Europe is growing significantly due to the tremendous support from governments for infectious diseases surveillance and the increasing adoption of advanced diagnostic technologies across all health care settings. Multiplex PCR systems have been incorporated into the clinical workflow in countries such as Germany, the UK, and France, significantly contributing to early diagnosis and better outcomes for patients. Moreover, increasing public awareness towards rapid diagnostics, a rising aging population susceptible to infections, and increasing collaborations between diagnostic companies and research institutes in Europe to boost their functional research are aiding the market growth in the region.

Moderate growth in the syndromic multiplex diagnostics market analysis is in Latin America, which is attributed to gradual improvements in healthcare infrastructure coupled with efforts by various government agencies to combat the outspread of infectious diseases. While countries such as Brazil and Mexico are putting investment towards diagnostic technologies, widespread limitations of access to healthcare in rural areas and a lack of resources for public health will continue to inhibit the rapid uptake of such technologies.

The market in MEA is witnessing steady growth due to the increasing knowledge about syndromic testing and combating communicable diseases. Healthcare infrastructure discrepancies, economic barriers, and a deficiency of skilled professionals prevent the widespread availability of cutting-edge diagnostic platforms.

Key Players:

Syndromic multiplex diagnostics market companies are bioMérieux SA, Luminex Corporation (a DiaSorin company), QIAGEN N.V., BioFire Diagnostics (a bioMérieux company), GenMark Diagnostics, Hologic Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers, Abbott Laboratories, Becton, Dickinson and Company (BD), Mobidiag Ltd (part of Hologic), Seegene Inc., Applied BioCode, Cepheid (a Danaher company), Randox Laboratories Ltd, AusDiagnostics Pty Ltd, Genetic Signatures Ltd, OpGen Inc., Fast Track Diagnostics (a Siemens Healthineers company), and other players.

Recent Developments:

  • January 2024 – QIAGEN launched two new syndromic testing panels for its QIAstat-Dx systems in India, the Gastrointestinal Panel 2 and the Meningitis/Encephalitis Panel. They add to the previously approved Respiratory SARS-CoV-2 Panel, which had been approved for emergency use in 2020. The new panels have gained regulatory approval from the Central Drugs Standard Control Organization (CDSCO), enabling healthcare professionals in India to conduct quicker, simpler, and more precise diagnostics.

  • April 2024 – Roche Group member GenMark launched the ePlex system under a new name as the cobas ePlex system. This global introduction under the highly recognized cobas brand is a testament to Roche's continued investment in platform-wide enhancements, including raw material procurement, manufacturing, and quality control improvements.

    Syndromic Multiplex Diagnostics Market Report Scope:
    Report Attributes Details
    Market Size in 2024 USD 2.87 Billion 
    Market Size by 2032 USD 4.13 Billion 
    CAGR CAGR of 4.71% From 2025 to 2032
    Base Year 2024
    Forecast Period 2025-2032
    Historical Data 2021-2023
    Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
    Key Segments • By Product & Service (Reagents & Consumables, Instruments/Systems, Software & Services)
    • By Syndrome/Disease Type (Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Bloodstream Infections, Central Nervous System (CNS) Infections, Urinary Tract Infections (UTIs), Others)
    • By Technology (PCR-based, Microarrays, Next-Generation Sequencing (NGS), Isothermal Nucleic Acid Amplification, Other Molecular Diagnostic Technologies)
    • By End User (Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutions, Others (e.g., Ambulatory Centers))
    Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
    Company Profiles Syndromic multiplex diagnostics market companies are bioMérieux SA, Luminex Corporation (a DiaSorin company), QIAGEN N.V., BioFire Diagnostics (a bioMérieux company), GenMark Diagnostics, Hologic Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers, Abbott Laboratories, Becton, Dickinson and Company (BD), Mobidiag Ltd (part of Hologic), Seegene Inc., Applied BioCode, Cepheid (a Danaher company), Randox Laboratories Ltd, AusDiagnostics Pty Ltd, Genetic Signatures Ltd, OpGen Inc., Fast Track Diagnostics (a Siemens Healthineers company), and other players.